

The invention refers to modified cytokines that represent conjugation product between a cytokine selected from TNF or IFN γ and a ligand of the CD 13 receptor. More particularly, the invention refers to cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.